NewsResearch
FDA Approval: Pembrolizumab — tissue-agnostic (MSI-H) for Cancer
FDA approved Pembrolizumab — tissue-agnostic (MSI-H), an anti-PD-1 checkpoint inhibitor, for certain cancers with specific biomarkers. What was approved, the evidence, and what it does and doesn't mean.
Original commentary from the Cancer Explained editorial team.
Please note: this page is educational only — it is not medical advice, and it does not speculate about anyone’s health beyond reliable public reporting. For questions about your own health, talk with your healthcare team.
In brief
FDA approved Pembrolizumab — tissue-agnostic (MSI-H) — anti-PD-1 checkpoint inhibitor — for certain cancers with specific biomarkers. This page explains what that means in plain language and where the limits are.
Approval at a glance
| Field | Detail |
|---|---|
| Drug | Pembrolizumab — tissue-agnostic (MSI-H) |
| Regulator | FDA |
| Date | 2017 |
| Cancer type | Cancer |
| Treatment class | anti-PD-1 checkpoint inhibitor |
| Eligible population | Certain cancers with specific biomarkers |
| Approval type | first tissue-agnostic approval |
What was approved
Pembrolizumab — tissue-agnostic (MSI-H) (anti-PD-1 checkpoint inhibitor) received a first tissue-agnostic approval from the FDA for use in certain cancers with specific biomarkers, reported for 2017. Eligibility is defined by the official label; whether it fits a specific person is a clinical decision.
The evidence behind it
The approval was based on the clinical evidence summarized in the FDA's announcement and the product label.
What this does and doesn't change
Approvals like this can expand options for certain cancers with specific biomarkers, but they do not change care for everyone, and access, cost, and side effects still matter.
What to keep in perspective
- An approval defines who is eligible in general terms; whether it fits a specific person is an individual clinical decision.
- Approval is not a promise of cure or of benefit for every patient — it means the evidence met the regulator's bar for this use.
- Labels and evidence can change over time as more data arrive.
If this is relevant to you, questions to ask
- Am I in the group this treatment was approved for?
- How does it compare with my current options?
- What are the costs, logistics, and side effects?
Sources
This article was written from the sources below, which were checked on the source-check date shown above.
How this article was prepared
Prepared by Cancer Explained's AI-assisted editorial system and checked against the sources listed below. This article has not been reviewed by a healthcare professional unless a named reviewer is specifically shown.
Cancer Explained is published by the National Cancer Information Foundation as a nonprofit-oriented public-interest education project. It is not a diagnostic service, does not recommend treatments, and is not for emergencies.
Found an error, a broken source link, outdated information, or wording that feels insensitive? Report it here — we log and act on material corrections.